{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:48:31Z","timestamp":1777949311604,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"DOI":"10.1186\/s13052-026-02235-4","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:06:18Z","timestamp":1774357578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging eosinophilic esophagitis: healthcare transition from pediatric to adult patients"],"prefix":"10.1186","volume":"52","author":[{"given":"Edoardo Vincenzo","family":"Savarino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Giodice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0548-6226","authenticated-orcid":false,"given":"Marianna","family":"Morani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Fardella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Beatrice","family":"Bil\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"De Bortoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Penagini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Renzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Strisciuglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Vespa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2235_CR1","doi-asserted-by":"publisher","first-page":"175628482412495","DOI":"10.1177\/17562848241249570","volume":"17","author":"EV Savarino","year":"2024","unstructured":"Savarino EV, Barbara G, Bilo MB, et al. Eosinophilic esophagitis in adults and adolescents: epidemiology, diagnostic challenges, and management strategies for a type 2 inflammatory disease. Th Adv Gastroenterol. 2024;17:17562848241249570.","journal-title":"Th Adv Gastroenterol"},{"issue":"6","key":"2235_CR2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.dld.2024.02.005","volume":"56","author":"N de Bortoli","year":"2024","unstructured":"de Bortoli N, Visaggi P, Penagini R, et al. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis - Definition, Clinical Presentation and Diagnosis. Dig Liver Dis. 2024;56(6):951\u201363.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"2235_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.anai.2022.10.026","volume":"130","author":"B Underwood","year":"2023","unstructured":"Underwood B, Troutman TD, Schwartz JT. Breaking down the complex pathophysiology of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2023;130(1):28\u201339.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"13","key":"2235_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2021.14920","volume":"326","author":"A Muir","year":"2021","unstructured":"Muir A, Falk GW. Eosinophilic Esophagitis: A Review. JAMA. 2021;326(13):1310\u20138.","journal-title":"JAMA"},{"key":"2235_CR5","doi-asserted-by":"publisher","first-page":"175628482098086","DOI":"10.1177\/1756284820980860","volume":"14","author":"P Visaggi","year":"2021","unstructured":"Visaggi P, Savarino E, Sciume G, et al. Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. Th Adv Gastroenterol. 2021;14:1756284820980860.","journal-title":"Th Adv Gastroenterol"},{"issue":"12","key":"2235_CR6","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.dld.2021.05.017","volume":"53","author":"MV Lenti","year":"2021","unstructured":"Lenti MV, Savarino E, Mauro A, et al. Diagnostic delay and misdiagnosis in eosinophilic oesophagitis. Dig Liver Dis. 2021;53(12):1632\u20139.","journal-title":"Dig Liver Dis"},{"key":"2235_CR7","doi-asserted-by":"crossref","unstructured":"Visaggi P, Del Corso G, Solinas I, et al. Adaptive behaviors, esophageal anxiety, and hypervigilance modify the association between dysphagia perception and histological disease activity in eosinophilic esophagitis. Am J Gastroenterol. 2024 Dec 30.","DOI":"10.14309\/ajg.0000000000003272"},{"issue":"11","key":"2235_CR8","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1136\/gutjnl-2023-329873","volume":"72","author":"P Visaggi","year":"2023","unstructured":"Visaggi P, Barberio B, Del Corso G, et al. Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis. Gut. 2023;72(11):2019\u201330.","journal-title":"Gut"},{"issue":"7","key":"2235_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.dld.2024.02.020","volume":"56","author":"N de Bortoli","year":"2024","unstructured":"de Bortoli N, Visaggi P, Penagini R, et al. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis-Current Treatment and Monitoring. Dig Liver Dis. 2024;56(7):1173\u201384.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"2235_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jpn3.12188","volume":"79","author":"J Amil-Dias","year":"2024","unstructured":"Amil-Dias J, Oliva S, Papadopoulou A, et al. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2024;79(2):394\u2013437.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"2235_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1442-2050.2011.01315.x","volume":"26","author":"ES Dellon","year":"2013","unstructured":"Dellon ES, Jones PD, Martin NB, et al. Health-care transition from pediatric to adult-focused gastroenterology in patients with eosinophilic esophagitis. Dis Esophagus. 2013;26(1):7\u201313.","journal-title":"Dis Esophagus"},{"key":"2235_CR12","doi-asserted-by":"crossref","unstructured":"Ferris M, Cohen S, Haberman C, et al. Self-management and transition readiness assessment: development, reliability, and factor structure of the starx questionnaire. j pediatr nurs. 2015 sep-oct;30(5):691\u20139.","DOI":"10.1016\/j.pedn.2015.05.009"},{"key":"2235_CR13","unstructured":"Oliva S, Rea F, Renzo S, et al. PedEoEvolution: optimizing management of pediatric and adolescent Eosinophilic Esophagitis in Italy - a comprehensive approach to diagnosis, treatment, and follow-up (under review)."},{"issue":"4","key":"2235_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1053\/j.gastro.2019.09.052","volume":"158","author":"I Hirano","year":"2020","unstructured":"Hirano I, Furuta GT. Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis. Gastroenterology. 2020;158(4):840\u201351.","journal-title":"Gastroenterology"},{"issue":"4","key":"2235_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/gutjnl-2011-301817","volume":"62","author":"I Hirano","year":"2013","unstructured":"Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489\u201395.","journal-title":"Gut"},{"issue":"3","key":"2235_CR16","first-page":"1","volume":"30","author":"MH Collins","year":"2017","unstructured":"Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1\u20138.","journal-title":"Dis Esophagus"},{"key":"2235_CR17","unstructured":"Savarino EV, et al. Italian eoexpert panel recommendation for disease control, switching criteria & follow-up in eosinophilic esophagitis from pediatric to adult age - under review (accepted by therapeutic advances in Gastroenterology)."},{"issue":"7","key":"2235_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/1054-139X(93)90143-D","volume":"14","author":"RW Blum","year":"1993","unstructured":"Blum RW, Garell D, Hodgman CH, et al. Transition from child-centered to adult health-care systems for adolescents with chronic conditions. A position paper of the Society for Adolescent Medicine. J Adolesc Health. 1993;14(7):570\u20136.","journal-title":"J Adolesc Health"},{"key":"2235_CR19","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cgh.2021.10.028","volume":"20","author":"NC Chang","year":"2022","unstructured":"Chang NC, et al. A Gap in Care Leads to Progression of Fibrosis in Eosinophilic Esophagitis Patients. Clin Gastroenterol Hepatol. 2022;20:1701\u2013e17082.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2235_CR20","unstructured":"University of North Carolina. (n.d.). UNC STARx Program. UNC School of Medicine. Available at: https:\/\/www.med.unc.edu\/transition\/transition-tools\/trxansition-scale [last access: March 2025]."},{"issue":"1","key":"2235_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/MPG.0000000000001415","volume":"65","author":"S Eluri","year":"2017","unstructured":"Eluri S, Book WM, Kodroff E, et al. Lack of Knowledge and Low Readiness for Health Care Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. J Pediatr Gastroenterol Nutr. 2017;65(1):53\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2235_CR22","unstructured":"University of North Carolina. (n.d.). Versions of the STARx Questionnaire. UNC School of Medicine. Available at: https:\/\/www.med.unc.edu\/transition\/transition-tools\/trxansition-scale\/versions-of-the-starx-questionnaire\/ [last access: March 2025]."}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-026-02235-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T22:47:30Z","timestamp":1777848450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13052-026-02235-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1186\/s13052-026-02235-4","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All claims expressed in this article serve only as a reference to best practice, and the diagnosis and treatment of the disease is determined by the physician on a case-by-case basis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author disclaimer"}},{"value":"EVS has served as speaker for Abbvie, Agave, AGPharma, Alfasigma, Aurora Pharma, CaDiGroup, Celltrion, Dr Falk, EG Stada Group, Fenix Pharma, Fresenius Kabi, Galapagos, Janssen, JB Pharmaceuticals, Innovamedica\/Adacyte, Malesci, Mayoly Biohealth, Omega Pharma, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Tillots, Unifarco; has served as consultant for Abbvie, Agave, Alfasigma, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Dr. Falk, Fenix Pharma, Fresenius Kabi, Janssen, JB Pharmaceuticals, Merck & Co, Nestl\u00e8, Reckitt Benckiser, Regeneron, Sanofi, SILA, Sofar, Synformulas GmbH, Takeda, Unifarco; he received research support from Pfizer, Reckitt Benckiser, SILA, Sofar, Unifarco, Zeta Farmaceutici.RG no conflicts of interest to declare. MM is a consultant of PharmaLex Italy S.p.A. and has no conflicts of interest in this research. MB is a consultant of PharmaLex Italy S.p.A. and has no conflicts of interest in this research. MF is a consultant of PharmaLex Italy S.p.A. and has no conflicts of interest in this research. MBB received fees for lectures from ALK, AstraZeneca, Chiesi, GSK, and Sanofi. NDB received consulting fee from Sofar, Reckitt-Benkiser, Dr. Falk, Malesci, Alfasigma, and Sanofi Genzyme; and for the participation to Advisory Board: Astra Zeneca, Dr. Falk. ADS no conflict of interest to declare. RP received consulting fees from Dr Falk Pharma and Sanofi for analysis conduction, or for the participation in Advisory Boards and\/or Conferences. FR received consulting fees for analysis, conduction, and\/or participation in Advisory Boards and\/or Conferences from Sanofi. SR received consulting fees for analysis, conduction, and\/or participation in Advisory Boards and\/or Conferences from Sanofi. CR served as Consultant for Nestle\u2019 Heath Science. He received consulting fees for analysis, conduction, and\/or participation in Advisory Boards and\/or Conferences from Sanofi. GS no conflicts of interest to declare. IS received speaker and\/or consulting fees from Sanofi\/Regeneron. CS received consultant fee from Aboca S.p.A., and Sanofi. EV received speaker and\/or consulting fees from Sanofi\/Regeneron, Falk Pharma, Apollo Therapeutics, Recordati and Aurora Biofarma. SO received consulting fees from Sanofi, Alfasigma, Medtronic, and Bristol Myers Squibb. Received consulting fees for analysis, conduction, and\/or participation in Advisory Boards and\/or Conferences from Sanofi.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}